{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-26-000555","form_type":"8-K","ticker":"ASPI","cik":"0001921865","company_name":"ASP Isotopes Inc.","filed_at":"2026-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.767693+00:00","generated_at":"2026-05-16T06:07:05.367222+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ASP Isotopes invests ~$10M in Opeongo, gets right of first offer on medical isotope supply","bullets":["Purchased 4,356,918 Series Seed-1 Preferred shares of Opeongo at $2.2952 per share (approx $10M investment).","Opeongo is a biotech developing ECM modulators for fibrosis, inflammation, and cancer; co-founded by David Baram and Irit Sagi.","ASPI secures right of first offer to supply medical isotopes for any Opeongo pharmaceutical product (supply agreement to be negotiated).","Related party: ASPI CEO Paul Mann designated as Series Seed-1 Director of Opeongo; CMO Todd Wider also a director."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-26-000555","json":"https://secwatch.observer/filing/0001477932-26-000555.json","markdown":"https://secwatch.observer/filing/0001477932-26-000555.md","text":"https://secwatch.observer/filing/0001477932-26-000555.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1921865/000147793226000555/0001477932-26-000555-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1921865/000147793226000555/aspi_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T06:07:05.367222+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"079e6ac8be3e7035a7ad3f7082c9f5db5fcd2967","claim":"ASP Isotopes Inc. entered into Series Seed-1 Preferred Stock Purchase Agreement with Opeongo, Inc. valued at $2.2952 per share (effective 2026-01-26).","evidence_excerpt":"On January 26, 2026, ASP Isotopes Inc., a Delaware corporation (“ ASP Isotopes ” or the “ Company ”), entered into a Series Seed-1 Preferred Stock Purchase Agreement (the “ Purchase Agreement ”) with Opeongo, Inc., a Delaware corporation (“ Opeongo ”), pursuant to which the Company agreed to purchase from Opeongo 4,356,918 shares of Opeongo’s Series Seed-1 Preferred Stock, $0.0001 par value per share (the “ Series Seed-1 Preferred Stock ”), at a price of $2.2952 per share","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1921865/000147793226000555/0001477932-26-000555-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Opeongo, Inc."},{"label":"Value","value":"$2.2952 per share"},{"label":"Effective","value":"2026-01-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}